Brief: Agilent Receives FDA Approval For Pd-L1 Ihc 22C3 Pharmdx In Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Carcinoma (Eoc)

Agilent Technologies

11/02/2026 11:47

Feb 11 (Reuters) - Agilent Technologies Inc A.N:

AGILENT RECEIVES FDA APPROVAL FOR PD-L1 IHC 22C3 PHARMDX IN EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CARCINOMA (EOC)

Source text: ID:nBw6GswTTa

Further company coverage: A.N

 ((Reuters.Briefs@thomsonreuters.com;))